KD Logo

Marinus Pharmaceuticals Inc [MRNS] stock for 20,583 USD was sold by Shafer Christina

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Marinus Pharmaceuticals Inc shares valued at $20,583 were sold by Shafer Christina on Feb 20 ’24. At $9.56 per share, Shafer Christina sold 2,153 shares. The insider’s holdings dropped to 60,308 shares worth approximately $81415.8 following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, MANNING MARTHA E sold 1,894 shares, netting a total of over 18,126 in proceeds. Following the sale of shares at $9.57 each, the insider now holds 52,966 shares.

Before that, Braunstein Scott had sold 11,850 shares from its account. In a trade valued at $117,789, the CHAIRMAN AND CEO traded Marinus Pharmaceuticals Inc shares for $9.94 each. Upon closing the transaction, the insider’s holdings decreased to 11,850 shares, worth approximately $0.3 million.

As published in a research note from Robert W. Baird on April 16, 2024, Marinus Pharmaceuticals Inc [MRNS] has been rated down from an Outperform to a Neutral and the price target has been revised to $2 from $20. Analysts at RBC Capital Mkts downgraded the stock from ‘”an Outperform”‘ to ‘”a Sector perform”‘ outlook in a report released in mid April. As of August 11, 2023, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for MRNS. Earlier on January 20, 2023, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for MRNS stock.

Analyzing MRNS Stock Performance

During the last five days, there has been a drop of approximately -9.40%. Over the course of the year, Marinus Pharmaceuticals Inc shares have dropped approximately -87.58%. Shares of the company reached a 52-week high of $11.2600 on 01/08/24 and a 52-week low of $1.1100 on 04/16/24. A 50-day SMA is recorded $1.8057, while a 200-day SMA reached $6.7428. Nevertheless, trading volume fell to 0.97 million shares from 1.47 million shares the previous day.

Support And Resistance Levels for Marinus Pharmaceuticals Inc (MRNS)

According to the 24-hour chart, there is a support level at 1.3100, which, if violated, would cause prices to drop to 1.2700. In the upper region, resistance lies at 1.4050. The next price resistance is at 1.4600. RSI (Relative Strength Index) is 30.75 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0738, which suggests the price will decrease in the coming days. Percent R is at 91.94%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Most Popular